Herpes zoster in kidney transplant recipients: protective effect of anti-cytomegalovirus prophylaxis and natural killer cell count. A single-center cohort study

Transpl Int. 2018 Feb;31(2):187-197. doi: 10.1111/tri.13076. Epub 2017 Oct 11.

Abstract

Despite its impact on quality of life and potential for complications, specific risk and protective factors for herpes zoster (HZ) after kidney transplantation (KT) remain to be clarified. We included 444 patients undergoing KT between November 2008 and March 2013. Peripheral blood lymphocyte subpopulations were measured at baseline and months 1 and 6. The risk factors for early (first post-transplant year) and late HZ (years 1-5) were separately assessed. We observed 35 episodes of post-transplant HZ after a median follow-up of 48.3 months (incidence rate: 0.057 per 1000 transplant-days). Median interval from transplantation was 18.3 months. Six patients (17.1%) developed disseminated infection. Postherpetic neuralgia occurred in 10 cases (28.6%). The receipt of anti-cytomegalovirus (CMV) prophylaxis with (val)ganciclovir decreased the risk of early HZ [adjusted hazard ratio (aHR): 0.08; 95% CI: 0.01-1.13; P-value = 0.062], whereas the natural killer (NK) cell at month 6 was protective for the occurrence of late HZ [aHR (per 10-cells/μl increase): 0.94; 95% CI: 0.88-1.00; P-value = 0.054]. In conclusion, two easily ascertainable factors (whether the patient is receiving anti-CMV prophylaxis and the NK cell count at month 6) might be potentially useful to tailor preventive strategies according to individual susceptibility to post-transplant HZ.

Keywords: anti-cytomegalovirus prophylaxis; herpes zoster; immunological monitoring; incidence; kidney transplantation; risk factors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antiviral Agents / administration & dosage*
  • Chemoprevention / methods
  • Cohort Studies
  • Cytomegalovirus / drug effects
  • Cytomegalovirus / isolation & purification
  • Cytomegalovirus Infections / drug therapy
  • Cytomegalovirus Infections / prevention & control*
  • Female
  • Ganciclovir / administration & dosage*
  • Graft Rejection
  • Graft Survival
  • Herpes Zoster / prevention & control*
  • Humans
  • Kidney Transplantation / adverse effects
  • Kidney Transplantation / methods*
  • Killer Cells, Natural / drug effects
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Prognosis
  • ROC Curve
  • Retrospective Studies
  • Risk Assessment
  • Transplant Recipients*

Substances

  • Antiviral Agents
  • Ganciclovir